Services Design Development Scientific Advice Project Management QA – Quality Assurance Monitoring Clinical Performance Data Management/eTrials Biostatistics Medical Writing Expert Statement Expertise Pharmacokinetics BA/BE Interactions Oncological trials Ophthalmological trials Inhalatives Transdermal Therapeutic Systems Children Sexual Hormones Therapeutic Expertise Clinical Development Phase I Phase II / Proof of Concept Phase III in OTC Phase III Non-Interventional Magnetic Marker Monitoring Medical Devices Nutrition Studies Clinical Pharmacology Unit Location Plan Capacity Technical Monitoring Ophthalmology Gynaecology Intensive Assessment Unit Clean Room Area Archive About Us Goals and Visions Our Experts Science Quality Library Presentations Library Publications Locations Career News Who is a healthy subject? German Pharm-Tox Summit 2017 in Heidelberg 2nd part of Introductory Course in Exploratory Medicines Development scheduled for February 2017 Introductory Course in Exploratory Medicines Development – taking place in our offices in Oberursel! 2nd Global Bioequivalence Harmonisation Initiative – a great success Quality Management Systems in Early Phase Trials Probanden The SocraTec Family SocraTec C&S SocraMetrics Cooperations
PASS ANVISA PAES Inhalatives Hormone replacement therapy Oncological patients Transdermal therapeutic system Phase IIa trials Training Product development Biopharmaceutical Lung US CFR 21 Part 11 Post authorisation OTC Monitoring Sore throat Legal representative Clinical Monitoring Project Management Source Data Verification Asthma CDM Pharmacodynamic studies FDA Authorities Drug Drug Interaction Pharmacokinetics Sample size estimation Scientific expertise Ocular tolerability FIM TTS Cardiovascular surveillance Database Oncology Ophthalmology Absorption Rhine Main area Uveitis Hypothalamic Creativity HTA Feasibility Efficacy Children HRT Standardisation Phase IIb trials Phase I Unit Dermal irritation SOP based Pituitary Clinical pharmacology unit Phase II Auditing Local tolerability Adrenocortical Good Clinical Practice Phase III Steady state Statistical Analysis Plan Biopharmaceutics Ophthalmological trials Healthy subjects HPA axis WinNonlin Audit Postmenopausal women Pharmacokintetics Protocol Ovulation inhibition IVIVC Early phase Pharmacology MCID NIS CRO GCP IMPD Oncologic network Competence Quality Management System Common cold Quality Assurance Design development ADAM CDSIC Safety Statistical services Thuringia Paediatricians CDISC First in human Phase IV Degeneration Dose linearity Experience GLP Data Management Plan Referral system DPI Edema Metered dose inhaler Expert Phase I Drug Food Interaction Patient recruitment AGAH Dry eye Copyright Bioavailability Xerostomia Bioequivalence Patch Pragmatism Legal Information ICF Protocol development Highly variable drugs Anaesthesiologist GCP training Allergy IB Clinical development program CRF Informed Consent Procedure Axis Spacious archive Clinical trials Non interventional Network Ophthalmologist Consultancy Gynaecological trials Female adolescents Sensitisation trials Absorption windows MDI Patients Life cycle management Clinical study Recruitment rates Endpoint Pulse oximetry plethysmography IEC US FDA Centralised procedure Macular Cough Subcontractor qualification DFI Sequential designs MMM Quality CDASH Investigators brochure Glaucoma COPD Pilot study Dry powder inhaler SocraTec C&S CRA DUS Scientific advice Intensive assessment station Patch adhesion Elpro DDI In vitro in vivo correlation Charcoal Data management Slit lamp microscopy Central surveillance system Statistical programming Biosimilars SDV Contraception Inspection EMA SAS Standard operating procedure Eye disease Data Validation Plan Biometrics Immunogenicity  
 
Menu

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All fine on front page